- Home
- MLR vs XNCR Comparison
MLR vs XNCR Comparison
Compare MLR & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLR
- XNCR
- Stock Information
- Founded
- MLR 1990
- XNCR 1997
- Country
- MLR United States
- XNCR United States
- Employees
- MLR N/A
- XNCR N/A
- Industry
- MLR Construction/Ag Equipment/Trucks
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- MLR Consumer Discretionary
- XNCR Health Care
- Exchange
- MLR Nasdaq
- XNCR Nasdaq
- Market Cap
- MLR 492.7M
- XNCR 547.8M
- IPO Year
- MLR 1994
- XNCR 2013
- Fundamental
- Price
- MLR $39.99
- XNCR $11.79
- Analyst Decision
- MLR Strong Buy
- XNCR Buy
- Analyst Count
- MLR 1
- XNCR 11
- Target Price
- MLR $64.00
- XNCR $22.20
- AVG Volume (30 Days)
- MLR 100.5K
- XNCR 1.2M
- Earning Date
- MLR 11-11-2025
- XNCR 11-05-2025
- Dividend Yield
- MLR 2.00%
- XNCR N/A
- EPS Growth
- MLR N/A
- XNCR N/A
- EPS
- MLR 3.64
- XNCR N/A
- Revenue
- MLR $975,860,000.00
- XNCR $146,929,000.00
- Revenue This Year
- MLR N/A
- XNCR $23.31
- Revenue Next Year
- MLR $26.85
- XNCR N/A
- P/E Ratio
- MLR $10.97
- XNCR N/A
- Revenue Growth
- MLR N/A
- XNCR N/A
- 52 Week Low
- MLR $33.81
- XNCR $6.92
- 52 Week High
- MLR $78.25
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- MLR 47.56
- XNCR 80.95
- Support Level
- MLR $38.40
- XNCR $10.24
- Resistance Level
- MLR $41.07
- XNCR $10.66
- Average True Range (ATR)
- MLR 1.25
- XNCR 0.61
- MACD
- MLR 0.21
- XNCR 0.14
- Stochastic Oscillator
- MLR 63.99
- XNCR 79.71
About MLR Miller Industries Inc.
Miller Industries Inc is engaged in the manufacturing of vehicle towing and recovery equipment. The company produces wreckers, car carriers, and trailer bodies under the Century, Vulcan, Challenger, Holmes, Champion, Chevron, Eagle, Titan, Jige, and Boniface brands. The products are sold in North America, Canada, and Mexico through independent distributors.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.